Cencora, Inc. (NYSE:COR) Shares Purchased by Moors & Cabot Inc.

Moors & Cabot Inc. raised its stake in Cencora, Inc. (NYSE:COR) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,991 shares of the company’s stock after buying an additional 66 shares during the quarter. Moors & Cabot Inc.’s holdings in Cencora were worth $447,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Prime Capital Investment Advisors LLC grew its holdings in shares of Cencora by 1.2% in the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock valued at $848,000 after purchasing an additional 46 shares during the period. Shepherd Financial Partners LLC boosted its holdings in Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock valued at $1,223,000 after purchasing an additional 46 shares during the last quarter. WASHINGTON TRUST Co grew its stake in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after buying an additional 46 shares during the period. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares during the period. Finally, Cullen Frost Bankers Inc. increased its holdings in shares of Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock worth $1,003,000 after buying an additional 47 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

COR has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $280.20.

Insider Buying and Selling

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,648 shares of company stock worth $3,382,462. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $258.09 on Friday. The company has a market cap of $50.05 billion, a P/E ratio of 36.71, a PEG ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $263.70. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The firm’s 50 day moving average price is $247.59 and its 200 day moving average price is $239.13.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.